O papel da Microbiota Intestinal na etiologia da Doença de Crohn: uma revisão integrativa / The role of the Intestinal Microbiota in the etiology of Crohn's Disease: an integrative review

Lorenna Ferreira da Silva, Matheus Alves Pacheco, Paola Veloso Pagung, Letícia Freitas de Castro Silva, Elisa Pinheiro Weber, Mariana Ramos Peixoto Melo, Maíra Mainart Menezes, Maíra Mainart Menezes, Fanny Ramos Dutra, Sara Oliveira Reis, Eduarda Paula Markus Xavier, Eduardo Horta Seabra Lana

Abstract


INTRODUÇÃO: A Doença de Crohn (DC), uma Doença Inflamatória Intestinal (DII) cuja patogênese é caracterizada por um desequilíbrio imunológico, é associada a fatores genéticos, ambientais e à microflora intestinal (MI). Isto posto, o presente artigo objetiva elucidar a relação entre MI e etiologia da DC. METODOLOGIA: Trata-se de uma Revisão Integrativa, com análise de 22 estudos publicados entre 2016 e 2020, disponíveis no portal da PubMed. RESULTADOS: A busca foi constituída por 4.782 artigos, com seleção de 22 estudos. A população amostral variou de 19 a 895 participantes. Observou-se que uma DII pode ser precedida por disbiose da MI, corroborando uma reação inflamatória local. Assim, determinou-se excesso de Enterococcus e Escherichia, associado a diminuição de Faecalibacterium, Gemmiger, Rominocuccus e Dialister. Ademais, dieta rica em sacarídeos, uso de antibióticos na infância e industrialização elevaram a incidência em ambientes urbanos. DISCUSSÃO: Na DC, a interação entre suscetibilidade genética, fatores ambientais e disbiose intestinal, resulta em comprometimento da barreira epitelial e consequente resposta imune anormal. CONCLUSÃO: Conclui-se que há uma forte relação entre disbiose intestinal e DC. Contudo, apesar das pesquisas pré-existentes, os fatores etiopatogênicos da DC não são bem elucidados. Portanto, ressalta-se a necessidade de estudos mais aprofundados acerca da temática proposta.

 


Keywords


Disbiose, Doença de Crohn, Microbiota intestinal.

References


Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. The Lancet. 2016 Apr; 386(10080):1741-1755

Zhaohua S et al. Update on intestinal microbiota in Crohn's disease 2017: mechanisms, clinical application, adverse reactions, and outlook. Journal of gastroenterology and hepatology. 2017; 32(11):1804-1812

Sahil K, Laura ER. The microbiome in Crohn's disease: role in pathogenesis and role of microbiome replacement therapies. Gastroenterology Clinics. 2017; 46(3):481-492

Tao Z et al. Urbanization and the gut microbiota in health and inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology. 2018; 15(7):440-452

Imhann F, Vila AV, Jan Bonder MB, Fu J, Gevers D, Visschedijk MC et al. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut. 2017; 67 (1), 108-119

Khan, I.; Ullah, N.; Zha, L.; Bai, Y.; Khan, A.; Zhao, T.; et al. Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens. 2019; 8(3):126

Kowalska-Duplaga, K et al. Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn’s disease. Scientific reports. 2019; 9(1):1-11

Rapozo DC, Bernardazzi C, De Souza HSF. Diet and microbiota in inflammatory bowel disease: The gut in disharmony. World journal of gastroenterology. 2017; 23(12):2124

Mondot S, Lepage P, Seksik P, et al. Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgery. Gut. 2016;65(6):954-962.

Franzosa EA, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nature microbiology, 2019; 4(2):293-305

Lichtenstein L, Avni-biron I, Ben-bassat O. Probiotics and prebiotics in Crohn's disease therapies. Best Practice & Research Clinical Gastroenterology. 2016; 30(1):81-88

Bjarnason I, Sission G, Hayee B. A randomised, double‑blind, placebo‑controlled trial of a multi‑strain probiotic in patients with asymptomatic ulcerative colitis and Crohn’s disease. Springer Inflammopharmacology. 2019; 27(3): 465–473

Yılmaz I, Dolar ME, Özpınar H. Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: A randomized controlled trial. Turk J Gastroenterol. 2019; 30(3):242–253

Svolos V, et al. Treatment of active Crohn’s disease with an ordinary food-based diet that replicates exclusive enteral nutrition. Gastroenterology. 2019; 156(5):1354-1367

Cox SR, et al. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial. Gastroenterology. 2020;158(1):176-188

Nishino K, et al. Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease. Journal of gastroenterology. 2018;53(1):95-106

Sprockett D, et al. Treatment-Specific Composition of the Gut Microbiota Is Associated With Disease Remission in a Pediatric Crohn’s Disease Cohort. Inflamm Bowel Dis. 2019;25(12):1927-1938.

Von Martels JZH, et al. Riboflavin supplementation in patients with Crohn’s disease (RISE-UP study). Journal of Crohn’s and Colitis, 2020; 14(5):595-607

He Z, et al. Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn's disease complicated with inflammatory mass. Scientific reports, 2017; 7(1):4753

Sokol H, et al. Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study. Microbiome, 2020; 8(1):12

Magro D, et al. Remission in Crohn’s disease is accompanied by alterations in the gut microbiota and mucins production. Nature Research, 2019; 9: 13263.

Pigneur B, et al. Mucosal Healing and Bacterial Composition in Response to Enteral Nutrition Vs Steroid-based Induction Therapy—A Randomised Prospective Clinical Trial in Children With Crohn’s Disease. Journal of Crohn's and Colitis, 2019; 846–855




DOI: https://doi.org/10.34117/bjdv7n7-112

Refbacks

  • There are currently no refbacks.